AP NEWS
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Stereotaxis Announces Next Generation Robotic Magnetic Navigation System and Imaging System

May 9, 2019

-- Innovative robotic surgery system, Stereotaxis Genesis™ RMN, enriches robotic magnetic navigation with increased efficiency, reduced size, and enhanced lab experience -- Genesis RMN System to be available in combination with Stereotaxis Imaging Model S, a next-generation x-ray system offered as part of a complete robotic electrophysiology lab solution -- Combined technologies greatly enhance the accessibility and affordability of robotics in electrophysiology

ST. LOUIS, May 09, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, introduced today Stereotaxis Genesis RMN, the next-generation robotic platform and a significant advancement in robotic magnetic navigation technology.

“I am excited and pleased to introduce Stereotaxis Genesis, the future of robotic electrophysiology,” said David Fischel, Chairman and CEO of Stereotaxis. “Genesis is a new beginning for Stereotaxis. It is the tangible reflection of Stereotaxis’ commitment to innovation that improves patient care, enhances the physician experience, and enables broad availability of robotic electrophysiology.”

The Stereotaxis Genesis RMN system provides the established benefits and reliability of robotic magnetic navigation in a highly innovative architecture that is faster, smaller, lighter and more flexible. Since the original launch of the Niobe® I system in 2003, improvements in Stereotaxis’ robotic system have remained iterative. Genesis RMN utilizes novel smaller magnets that rotate along their center of mass and are held by flexible robotic arms. This mechanism allows for instantaneous responsiveness to physician control and the flexibility to accommodate an increased range of motion. The Genesis RMN system’s significant reduction in size will improve the patient experience and provides physicians and nurses greater access to the patient during the procedure. The system represents a platform able to accommodate significant innovation in the future.

Stereotaxis Genesis RMN is being launched concurrently with Stereotaxis Imaging Model S as an integrated complete solution for a robotic interventional operating room. Stereotaxis Imaging Model S is a single-plane full-power x-ray system designed to be specifically available with the Genesis RMN system. It includes the c-arm, powered table, motorized boom, and large high-definition monitors. Developed in collaboration with Omega Medical Imaging, Stereotaxis Imaging incorporates modern fluoroscopy technology designed to support high quality imaging while minimizing radiation exposure for patients and physicians. The combination of Genesis RMN with Stereotaxis Imaging in a tightly integrated fashion significantly reduces the cost of acquisition, the ongoing cost of ownership, and the complexity of installation of a robotic electrophysiology practice.

“Dr. Natale and I had the opportunity to observe the Genesis and Stereotaxis Imaging systems in person,” said Dr. J. David Burkhardt, cardiac electrophysiologist, Texas Cardiac Arrhythmia Institute at St. David’s Medical Center. “I consider this a significant and impressive leap forward, and am excited to see the positive impact of this innovation on patient care, procedure efficiency and the overall experience in the electrophysiology lab.”

“We are enthusiastic about the reinvigorated robotic innovation by Stereotaxis and are excited to see how this technology advances the field of electrophysiology,” added Dr. Andrea Natale, cardiac electrophysiologist and Executive Medical Director, Texas Cardiac Arrhythmia Institute at St. David’s Medical Center.Stereotaxis Genesis RMN is CE marked and available for commercialization across various EU geographies. Availability in other global geographies is subject to regulatory approvals, which will be pursued in the coming months. Stereotaxis Imaging Model S has FDA clearance, CE mark, and is commercially available in the US, EU and certain other global geographies. Stereotaxis Imaging Model S is compatible with Niobe.

“It is very exciting and gratifying that we can improve clinical performance, as well as improve physician and patient experiences, while reducing cost. I want to thank the many Stereotaxis team members and external suppliers that made Genesis a reality. We are delighted to collaborate with Omega Medical Imaging and I want to thank them for making the vision of a complete robotic electrophysiology lab a reality,” said David Fischel, Chairman and CEO of Stereotaxis.

“Omega Medical Imaging prides itself on a long-standing commitment to providing the most reliable and technically advanced interventional imaging systems that put patient and staff safety at the forefront. We are excited to partner with Stereotaxis to advance the future of electrophysiology,” said Brian Fleming, President and CEO of Omega Medical Imaging.

Photos accompanying this announcement are available at: http://www.globenewswire.com/NewsRoom/AttachmentNg/bab5021e-d0eb-46cb-9354-5a6e3f5b4f40http://www.globenewswire.com/NewsRoom/AttachmentNg/4cb121e7-eedb-4856-977d-3b6cd1b10a3d

About Omega Medical ImagingOmega Medical Imaging, based in Sanford, Florida USA, is an innovator in the design, manufacture, delivery, and support of Interventional X-Ray Imaging devices for hospitals and healthcare facilities around the globe.

About StereotaxisStereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Over 100 issued patents support the Stereotaxis platform. Stereotaxis’ robotic technology has received various regulatory clearances in the United States, European Union, Japan, Canada, China, and elsewhere. The Stereotaxis Genesis RMN System is CE marked and will become available in other global geographies subject to regulatory approvals. Stereotaxis Imaging Model S is CE marked and FDA cleared. For more information, please visit www.stereotaxis.com.

This press release includes statements that may constitute “forward-looking” statements by Stereotaxis (the Company), usually containing the words “believe”, “estimate”, “project”, “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to raise additional capital on a timely basis and on terms that are acceptable, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness, or to obtain additional financing, in either case on acceptable terms, continued acceptance of the Company’s products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from healthcare reform in the United States, including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company’s control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

Stereotaxis Contacts: Omega Medical Imaging Contacts: David Fischel Brian Fleming Chairman and CEO President and CEO Martin C. Stammer Megan Grosz CFO Director of Sales and Marketing 314-678-6100 407-323-9400 investors@stereotaxis.com info@omegamedicalimaging.com